What did Cowen say in its March 16, 2026 NEO analyst rating

Cowen & Co. reiterated a **Buy** on March 16, 2026, saying reimbursement changes could boost 2026 revenue **3–4%**. The firm maintained its view rather than raising a price target, noting the catalyst as supportive but not yet fully reflected in consensus estimates.

Why did William Blair maintain Market Perform on NeoGenomics

William Blair kept **Market Perform** on March 16, 2026 after noting a 'much-needed positive catalyst.' The firm saw the catalyst as helpful but insufficient to change its medium-term revenue or margin outlook, so it left its rating unchanged.

Are there new price targets for NEO after these notes

No new price targets were issued in the March 16, 2026 notes. Both Cowen and William Blair maintained existing ratings without updating their published price targets, so investors must rely on prior targets and current fundamentals.

How should investors use the NEO analyst rating and Meyka grade

Use the NEO analyst rating alongside Meyka AI’s **B** grade as one input in research. The grade blends benchmark, sector, growth, and analyst consensus. Combine these signals with financials and reimbursement trends before making position decisions.

Analyst Ratings

NEO NeoGenomics, Inc. Maintained: Cowen Buy, William Blair Market Perform Mar 2026

ByHuzaifa Zahoor March 17, 2026

On March 16, 2026 the NEO analyst rating update showed Cowen & Co. kept Buy and William Blair kept Market Perform. Both firms published their verdicts during morning coverage, with Cowen citing reimbursements that could lift 2026 revenue by 3–4%, and William Blair noting a recent positive catalyst for the story. The two actions were both marked as Maintained and produced small intraday moves: Cowen coverage coincided with a 0.12% ($0.01) change and William Blair with a 0.24% ($0.02) change. Meyka AI rates NEO with a grade of B and tracks these shifts in real time.